Implications of Tricuspid Regurgitation Severity in Patients Undergoing Mitral Transcatheter Edge-to-Edge Repair
Abstract Body (Do not enter title and authors here): Background – Prognostically-meaningful tricuspid regurgitation (TR) surrounding transcatheter edge-to-edge repair (TEER) for mitral regurgitation (MR) is ill-defined. Objective – To explore the prevalence, correlates, and consequences of TR grades and postprocedural trends among mitral TEER patients. Methods – This is a single-center, retrospective analysis of isolated, first-time interventions. Pre-, intra-, and post-procedural aspects up to 1-year, of them the primary composite outcome of all-cause deaths or heart failure (HF) hospitalizations, were assessed according to continuous/categorical TR severity at baseline and 1-month post-TEER. Results – Overall, 1,287 individuals (60.3% males, age 78 (IQR, 69-85) years, 52.9% with functional MR) were included. Below-moderate, moderate, and above-moderate TR affected 48.4%, 29.5%, and 22.1% of patients, respectively. Increasing TR severity was accompanied by higher rates of functional, severe MR, greater comorbidity, and more advanced HF. Although not affecting technical and echocardiographic procedural success, moderate-and-above TR degrees were associated with higher incidence of mortality, HF admissions, and functional class III-IV post-procedure, with moderate-to-severe and greater TR independently conferring increased risks for the various outcomes (primary endpoint – HR 1.36, 95% CI 1.21-1.80, p=0.027). One-month postprocedural TR severity directly correlated with and was generally similar to or worse than its baseline counterpart. Rather than the direction/magnitude of change between the two, moderate-and-above grade at 1-month, observed in 37.1% of eligible patients, emerged as predictive of the primary outcome’s risk. Conclusion – Among mitral TEER patients, above-moderate TR at baseline and the closely-related moderate-and-above TR at 1-month post-procedure are highly prevalent and signal suboptimal outcomes. The potential benefit of simultaneously addressing such significant TR at the time of mitral TEER warrants further investigation.
Shechter, Alon
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Koren, Ofir
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Makar, Moody
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Skaf, Sabah
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Patel, Dhairya
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Chakravarty, Tarun
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Makkar, Raj
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Siegel, Robert
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Taheri, Homa
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Nagasaka, Takashi
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Gupta, Aakriti
( Cedars-Sinai Medical Center
, Los Aeles
, California
, United States
)
Kaewkes, Danon
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Patel, Vivek
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Suruga, Kazuki
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Dhillon, Manvir
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Koseki, Keita
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Author Disclosures:
Alon Shechter:DO NOT have relevant financial relationships
| Ofir Koren:No Answer
| Moody Makar:No Answer
| Sabah Skaf:No Answer
| Dhairya Patel:No Answer
| Tarun Chakravarty:No Answer
| Raj Makkar:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Boston Scientific:Active (exists now)
; Employee:Cedars-Sinai Medical Center:Active (exists now)
; Research Funding (PI or named investigator):Protembis:Active (exists now)
; Research Funding (PI or named investigator):PiCardia:Active (exists now)
; Research Funding (PI or named investigator):Abbott Vascular:Active (exists now)
; Research Funding (PI or named investigator):Medtronic:Active (exists now)
; Research Funding (PI or named investigator):Edwards LifeSciences:Active (exists now)
| Robert Siegel:DO NOT have relevant financial relationships
| HOMA TAHERI:DO NOT have relevant financial relationships
| TAKASHI NAGASAKA:DO NOT have relevant financial relationships
| Aakriti Gupta:DO have relevant financial relationships
;
Speaker:Boston Scientific:Past (completed)
; Speaker:Shockwave:Past (completed)
| Danon Kaewkes:DO NOT have relevant financial relationships
| Vivek Patel:DO NOT have relevant financial relationships
| Kazuki Suruga:DO NOT have relevant financial relationships
| Manvir Dhillon:DO NOT have relevant financial relationships
| Keita Koseki:No Answer